Master of Science in Translational Medicine Program

Faculty & Research Mentors at City of Hope
Karen Aboody, MD
Dr. Aboody, Professor at the Department of Developmental & Stem Cell Biology, received her MD from Mount Sinai School of Medicine. A major research focus of her laboratory is to modify and develop human neural stem cells into a novel therapeutic vehicle for delivering different cancer therapeutic agents to tumor sites in animal models.

David Ann, PhD
Dr. Ann, Professor at the Department of Diabetes Complications & Metabolism, received his PhD from Purdue University. His laboratory is investigating cancer metabolism to identify novel nutrient-restriction cancer therapy. A major focus of his team is to dissect the molecular mechanism by which tumor cells become auxotrophic for arginine.

Saro Armenian, DO, MPH
Dr. Armenian, Associate Professor at the Department of Pediatrics and Population Sciences, is the Director of Childhood Cancer Survivorship Clinic. Dr. Armenian's research focuses on understanding the effect of childhood cancer on cardiovascular disease and on developing strategies for cardiovascular screening of cancer survivors.

Kimlin Ashing, PhD
Dr. Ashing, Professor at the Department of Population Sciences, is the Director of Center of Community Alliance for Research and Education. Her focus is directed at understanding how social disparities impact health and patient centered outcomes with the goal of developing strategies to improve quality of life and reduce health inequities.

Behnam Badie, MD
Dr. Badie, Vice Chair and Professor at the Department of Surgery, received his MD from UCLA. Dr. Badie's research focuses on exploring novel immunotherapeutic strategies through the activation of microglia and macrophages to treat malignant brain tumors. He is also developing minimally invasive devices to deliver drugs into brain tumors.

Adam Bailis, PhD
Dr. Bailis, Associate Professor at the Department of Molecular and Cellular Biology, received his PhD from Albert Einstein College of Medicine. Dr. Bailis's research is focused on understanding the genetic control regulating genome stability and the consequences of loss of this genetic control.

Michael Barish, PhD
Dr. Barish, Chair of the Department of Developmental & Stem Cell Biology, received his PhD from Stanford University. His team is using large-field imaging techniques to visualize tumor initiating cells in patient-derived tumor xenografts, and the spatial relationships of migrating tumor cells and the sites of proliferation and engraftment.

Leslie Bernstein, PhD
Dr. Bernstein, Professor at the Division of Biomarkers of Early Detection and Prevention and Department of Population Sciences, received her PhD from UCLA. Her research utilizes data from the California Teacher Study to examine questions of cancer etiology, prevention and the impact of modifiable risk factors.

Andrea Bild, PhD
Dr. Bild, Professor at the Department of Medical Oncology & Therapeutics Research, received her PhD from University of Colorado, Denver. Her research team uses large-scale translational genomic and pharmacological studies to interrogate and treat tumor heterogeneity and evolution to refractory states.

Mark Boldin, PhD
Dr. Boldin, Associate Professor at the Department of Molecular & Cellular Biology, received his PhD from Weizmann Institute of Science (Israel). His current research focuses on defining the contribution of both microRNAs and long noncoding RNAs to the regulation of gene expression during hematopoiesis and the activation of immune responses.
Christine Brown, PhD  
Dr. Brown, Research Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received her PhD from UC Berkeley. As Associate Director of the T Cell Therapeutic Research Laboratory, she provides scientific oversight for the pre-clinical research program, as well as the development and refinement of CAR T cells.

John Burnett, PhD  
Dr. Burnett, Assistant Professor at the Department of Molecular & Cellular Biology, received his PhD from UC Berkeley. His laboratory focuses on engineering biological therapeutics, such as specialized RNA aptamers for targeted delivery and genome editing technologies, for genetic and infectious diseases.

Edouard Cantin, PhD  
Dr. Cantin, Professor at the Department of Molecular Imaging and Therapy, received his PhD from Cambridge University. Dr. Cantin’s research focuses on defining the mechanism by which herpes simplex virus contributes to encephalitis and keratitis, and dissecting the immunological responses that the host mounts against the virus.

Angelo Cardoso, MD, PhD  
Dr. Cardoso, Research Professor of Center for Gene Therapy, received his MD and PhD from Porto University and University of Paris XI Medical School, respectively. He studies how oncogenic signals interact with micro-environmental cues in an attempt to develop novel inhibitors targeting high-risk and refractory relapsed pediatric acute lymphoblastic leukemia.

Nadia Carlesso, MD, PhD  
Dr. Carlesso, Professor at the Department of Hematologic Malignancies Translational Science, received her PhD from U of Genoa & Dana-Farber Cancer Institute. She is investigating the role of the tumor microenvironment in leukemia progression to identify novel therapeutic approaches to defeat leukemia drug resistance and relapse.

Daniela Castanotto, PhD  
Dr. Castanotto, Research Professor at the Department of Medical Oncology and Therapeutics Research, received her PhD from University of Messina, Italy. Dr. Castanotto’s research focuses on the development of technology to promote uptake and activity of oligonucleotides as a potential means of targeting genes and affecting expression.

Wing-Chun (John) Chan, MD  
Dr. Chan, Dr. Norman and Melinda Payson Professor in Hematologic Cancer, received his MD from University of Hong Kong. Currently Dr. Chan's research focuses on using gene expression profiling to explore molecular classification of lymphoma and identify molecular signatures aimed at improving diagnosis and outcomes for lymphoma patients.

Saswati Chatterjee, PhD  
Dr. Chatterjee, Professor at the Department of Surgery, received her PhD from McGill University, Canada. Dr. Chatterjee's research is directed at using recombinant Adeno-Associated Virus vectors to genetically modify hematopoietic stem cells with the ultimate goal of treating an array of diseases including HIV and cancer.

Ammar Chaudhry, MD  
Dr. Chaudhry, Assistant Clinical Professor at the Department of Diagnostic Radiology, received his MD from University of South Florida College of Medicine and completed his training at the Johns Hopkins Department of Radiology. Dr. Chaudhry's research focus is on development and translation of noninvasive biomedical imaging technologies to improve diagnosis and treatment of cancer, metabolic and inflammatory disorders.

Chun-Wei (David) Chen, PhD  
Dr. Chen, Assistant Professor at the Department of Systems Biology, received his PhD from University of Rochester. His laboratory focuses on dissecting the epigenetic mechanisms underlying the therapeutic resistance in cancers, as well as developing leading-edge technology in precision epigenome editing and transcriptional regulations.
Jianjun Chen, PhD
Dr. Chen, Professor at the Department of Systems Biology, received his PhD from Chinese Academy of Sciences. His team focuses on basic and translational research associated with RNA/DNA epigenetics, especially N6 methyl-adenosine (m6A) RNA modification and TET protein mediated DNA methylation, in the development and drug response of cancers.

Mike Chen, MD, PhD
Dr. Chen, Associate Professor at the Division of Neurosurgery, received his MD from Thomas Jefferson University and a MS in Biomedical Engineering. He specializes in complex operations for the removal of brain and spine tumors. His laboratory investigates epigenetic pathways of metastasis and the development of novel medical devices.

Shiuan Chen, PhD
Dr. Chen, Chair of the Department of Cancer Biology, received his PhD from University of Hawaii. His team focuses on refining current treatment strategies and available drugs for better application against breast cancer. He also investigates how environmental chemicals and diet modulate the development of hormone-dependent cancers.

Wenyong Chen, PhD
Dr. Chen, Associate Professor at the Department of Cancer Biology, received his PhD from University of Alabama at Birmingham. His laboratory is interested in understanding epigenetic regulation of hematopoietic stem cell aging, leukemia development and drug resistance in leukemia stem cells.

Yuan Chen, PhD
Dr. Chen, Professor at the Department of Molecular Medicine, received her PhD from Rutgers University. Her laboratory is currently focusing on using chemical, biochemical and cellular approaches to study how changes in ubiquitin-like modifications influence major oncogenic pathways, such as c-Myc and Kras, in cancer pathogenesis.

Zhen Chen, PhD
Dr. Chen, Assistant Professor at the Department of Diabetes Complications & Metabolism, received her PhD from UC Riverside. Her lab investigates the role of non-coding RNA and chromatin remodeling in endothelial stress response and their implications in diabetes complications and cancer.

Warren Chow, MD
Dr. Chow, Clinical Professor at the Department of Medical Oncology and Therapeutics Research, received his MD from University of Health Sciences/the Chicago Medical School. Dr. Chow is interested in developing new therapeutics for treatment of sarcomas, which are less toxic and more efficacious.

Thanh Dellinger, MD
Dr. Dellinger, Assistant Professor at the Department of Surgery, received her MD from University of California Irvine School of Medicine. Dr. Dellinger’s research focuses on understanding the molecular pathways leading to ovarian and uterine cancers and the development of therapies to interdict these processes.

Sangeeta Dhawan, PhD
Dr. Dhawan, Assistant Professor at the Department of Translational Research & Cellular Therapeutics, received her PhD from Indian Institute of Science. Her laboratory focuses on identifying the epigenetic mechanisms that regulate the differentiation, regeneration, and survival of the insulin producing beta cells, in health and diabetes.

Don Diamond, PhD
Dr. Diamond, Professor at the Department of Immuno-Oncology, received his PhD from Harvard Medical School. His laboratory is focusing on developing a novel approach that uses attenuated salmonella encoding a short hairpin RNA to decrease the expression of molecules contributing to tumor rejection and controlling metastasis.
Richard Ermel, DVM, MPVM, PhD, DACLAM
Dr. Ermel, Director of Residency/Graduate Training Program in Laboratory Animal Medicine, received his PhD from UC Davis. His collaborative research includes identifying natural compounds with anti-cancer potential, new diabetic vascular disease inhibitors, and novel techniques for infectious disease detection.

Mingye Feng, PhD
Dr. Feng, Assistant Professor at the Department of Immuno-Oncology, received his PhD from Johns Hopkins School of Medicine. Dr. Feng's research is directed at understanding the mechanisms of macrophage-mediated immunosurveillance with the ultimate goal of developing novel anti-cancer immunotherapies.

Betty Ferrell, PhD
Dr. Ferrell, Director and Professor at the Division of Nursing Research and Education and the Department of Population Sciences, received her PhD from Texas Woman's University. Dr. Ferrell is interested in examining quality of life, pain management and palliative care for cancer patients.

Yuman Fong, MD
Dr. Fong, Chair and Professor at The Department of Surgery, received his MD from Cornell University Medical College. Dr. Fong's research is currently focusing on developing genetically engineered viruses to effectively target and destroy cancer cells, especially those that are resistant to chemo- and radiation therapies.

Stephen Forman, MD
Dr. Forman, Chair and Professor at The Department of Hematology and Hematopoietic Cell Transplantation, received his MD from University of Southern California. Dr. Forman's research is focused on developing genetically engineered CAR T cells to promote adoptive immunotherapy in the treatment of a wide range of cancers.

Patrick Fueger, PhD
Dr. Fueger, Associate Professor at the Department of Molecular & Cellular Endocrinology, received his PhD from Vanderbilt University. His laboratory is investigating molecular mechanisms that regulate glucose homeostasis during health and diabetes to identify novel strategies for increasing functional pancreatic islet mass.

Carlotta Glackin, PhD
Dr. Glackin, Associate Professor at the Department of Developmental & Stem Cell Biology, received her PhD from University of Southern California. Her laboratory focuses on understanding the molecular mechanisms underlying the functional properties of TWIST1 in cancer cells and developing TWIST1 inhibitors.

Nora Heisterkamp, PhD
Dr. Heisterkamp, Professor at the Department of Systems Biology, received her PhD from University of Rotterdam. Her team focuses on defining the molecular mechanism by which non-leukemia cells stimulate precursor B-lineage acute lymphoblastic leukemia cell growth and provide chemotherapeutic resistance via direct cell contact.

Robert Hickey, PhD
Dr. Hickey, Associate Professor at the Department of Molecular Medicine, received his PhD from City University of New York. Dr. Hickey is interested in using mass spectrometry to identify novel cancer related biomarkers and their corresponding mechanistic role in the development and progression of the cancer.

David Horne, PhD
Dr. Horne, Vice Provost & Chair of the Department of Molecular Medicine, received his PhD from MIT. His team focuses on developing new synthetic methods and strategies for the total synthesis of architecturally complex, biologically active natural compounds and their analogs as potential novel therapeutic agents.
**Wendong Huang, PhD**
Dr. Huang, Professor at the Department of Diabetes Complications & Metabolism, received his PhD from University of Texas Houston. His team is interested in identifying the molecular pathways by a group of nuclear receptors in regulating metabolism and in the pathogenesis of diabetes and cancer.

**Susanta Hui, PhD, DABR**
Dr. Hui, Clinical Professor at the Department of Radiation Oncology and the Director of Small Animal Imaging Core, received his PhD from University of Calcutta. The goal of his laboratory is to understand the response of bone and marrow to radiation treatment, the macro- and micro-environment of bone and marrow in malignancy.

**Janice Huss, PhD**
Dr. Huss, Associate Professor at the Department of Molecular & Cellular Endocrinology, received her PhD from University of Wisconsin-Madison. Her laboratory is investigating how the estrogen-related receptor family of orphan receptors regulates mitochondrial energy metabolism and growth in cardiac and skeletal muscle.

**Keiichi Itakura, PhD**
Dr. Itakura, Professor at The Department of Molecular and Cellular Biology, received his PhD from Tokyo Pharmaceutical College. His lab focuses on studies of the MRF-1/2 genes in modulating the energy utilization pathways and their roles in obesity and diabetes. Understanding the mechanisms related to these proteins is of primary interest.

**Rahul Jandial, MD, PhD**
Dr. Jandial, Associate Professor at the Department of Surgery, received his MD and PhD from USC and UC San Diego, respectively. He is interested in understanding the interplay between the brain microenvironment and metastatic cancer cells. He is also investigating the efficacy of a potential chemotherapeutic agent for treating metastatic brain cancer.

**Lei Jiang, PhD**
Dr. Jiang, Assistant Professor at the Department of Molecular & Cellular Endocrinology, received his PhD from Shanghai Institute for Biological Sciences. A major goal of his laboratory is to explore the coordinated metabolic adaptation under both normal physiological and specific pathological conditions for both cancer and diabetes.

**Jeremy Jones, PhD**
Dr. Jones, Associate Research Professor at the Department of Medical Oncology and Therapeutics Research, received his PhD from Stanford University School of Medicine. His lab is pursuing a variety of approaches, including new androgen receptor inhibitor development, to attenuate the impact of prostate, kidney and bladder cancers.

**Tijana Jovanovic-Talisman, PhD**
Dr. Talisman, Assistant Professor at the Department of Molecular Medicine, received her PhD from Columbia University. Her team uses pointillistic super-resolution imaging techniques that offer high spatial resolution and single-molecule sensitivity to study biological processes contributing to cancer and other diseases.

**John Kaddis, PhD**
Dr. Kaddis, Assistant Professor at the Department of Diabetes and Cancer Discovery Science, received his PhD from USC. He is currently focused on developing data systems and tools to address cutting edge questions relating to type 1 diabetes.

**Michael Kahn, PhD**
Dr. Kahn, Professor and Chair of the Department of Molecular Medicine, received his PhD from Yale University. His research team focuses on dissecting the signaling pathways in somatic and cancer stem cell development. Their second generation of CBP/β-catenin antagonist is currently in the clinical trials for various cancers and liver fibrosis.
Markus Kalkum, PhD
Dr. Kalkum, Professor at the Department of Molecular Imaging & Therapy and the Director of Mass Spectrometry & Proteomic Core, received his PhD from Freie Universität Berlin. His laboratory focuses on the development of novel proteomic technology to study pathogenic fungal and bacterial proteomes for vaccine development.

Fouad Kandeel, MD, PhD
Dr. Kandeel, Professor and Chair of the Department of Clinical Diabetes Endocrinology and Metabolism. Dr. Kandeel's work focuses on diabetes. He is testing the safety and efficacy of islet cell transplantation for type 1 diabetic patients and is also interested in understanding genetic factors contributing to type 2 diabetes and cardiovascular disease in Hispanics.

Rick Kittles, PhD
Dr. Kittles, Professor at the Department of Population Sciences and Director of Division of Health Equities, received his PhD from George Washington University. His research interest focuses on genetic and environmental factors and their mechanisms in contributing to disease risks and drug resistance.

Marcin Kortylewski, PhD
Dr. Kortylewski, Associate Professor at the Department of Immuno-Oncology, received his PhD from the University School of Medical Sciences, Poznan, Poland. His research is directed at developing a novel oligonucleotide approach to specifically target immune cells associated with tumors and attenuate STAT3's activity in promoting tumor growth.

Hsun Teresa Ku, PhD
Dr. Ku, Associate Professor at the Department of Translational Research and Cellular Therapeutics Research, received her PhD from Medical University of South Carolina. Her research in type 1 diabetes focuses on developing cell replacement therapy and identifying small molecules that modulate pancreatic insulin-producing beta cells and their progenitors.

Ya-Huei Kuo, PhD
Dr. Kuo, Associate Professor at the Department of Hematologic Malignancies Translational Science, received her PhD from University of Connecticut. Dr. Kuo's research is directed at understanding the molecular mechanisms involved in the development of acute myeloid leukemia to facilitate improved cancer treatments.

Larry W. Kwak, MD, PhD
Dr. Kwak, Professor, Department of Hematology and Hematopoietic Cell Transplantation, received his MD and PhD from Northwestern University. Dr. Kwak's laboratory focuses on studying novel immunotherapies to treat mantle cell lymphoma, a particularly aggressive type of lymphoma with a poor survival record.

Mark LaBarge, PhD
Dr. LaBarge, Professor at the Department of Population Sciences, received his PhD from Stanford University. His team specializes in developing human cell systems to dissect the micro-environmental and tissue-level changes in breast that arise with age for understanding why aging is a major risk factor for breast cancer.

James Lacey, PhD, MPH
Dr. Lacey, Associate Professor at the Department of Computation and Quantitative Medicine, received his PhD from University of Michigan, Ann Arbor. He is the Director of the Division of Cancer Etiology and is currently focused on developing tools to digitize the California Teachers Study database to make access and analysis more efficient.

Keane Lai, MD
Dr. Lai, Associate Clinical Professor at the Department of Pathology, received his MD from University of Pittsburgh. Dr. Lai is interested in defining the role that the Wnt/β-catenin signaling pathway plays in liver cancer and pancreatic cancer. His laboratory is also working toward identifying novel therapeutic targets in this pathway to combat pancreatic cancer.
Peter Lee, MD
Dr. Lee, Chair of the Department of Immuno-Oncology, received his MD from UC San Diego. His team utilizes high-dimensional flow cytometry, quantitative spatial image analysis and next-generation genomics to dissect how cancer impacts host immune responses in patients, and to develop novel treatments to restore their immune function.

Ling Li, PhD
Dr. Li, Assistant Professor at the Department of Hematologic Malignancies Translational Science, received his PhD from Zhejiang University. His laboratory focuses on determining the role of SIRT1 and p53 in regulating leukemia stem cell growth, with the ultimate goal of creating novel therapeutics for leukemia.

Ren-Jang Lin, PhD
Dr. Lin, Professor at the Department of Molecular & Cellular Biology, received PhD from Pennsylvania State University. His laboratory focuses on studying the molecular functions of RNA splicing factors with mutations associated with myelodysplastic syndromes, as well as designing microRNA-specific CRISPR/Cas9 library.

Yilun Liu, PhD
Dr. Liu, Associate Professor at the Department of Cancer Genetics & Epigenetics, received her PhD from Yale University. Her team focuses on uncovering the molecular etiologies of developmental abnormalities, premature aging syndromes, malignancies and chemo-resistance by the clinical mutations of the RECQ DNA helicases.

Qiang Lu, PhD
Dr. Lu, Professor at the Department of Developmental and Stem Cell Biology, received his PhD from University of California, San Diego. Dr. Lu's research is directed at understanding how neural stem cells decide to maintain their stemness or differentiate with the ultimate goal directed at developing treatments for brain cancers.

Ke Ma, MD, PhD
Dr. Ma, Associate Professor at the Department of Diabetes Complications & Metabolism, received her PhD from Baylor College of Medicine. Her team studies the regulatory networks mediating nutrient-sensing functions of circadian clock in tissue crosstalk between fat, muscle and liver in normal and pathological conditions.

Linda Malkas, PhD
Dr. Malkas, Professor at the Department of Molecular & Cellular Biology, received her PhD from City University of New York. Her laboratory is focusing on developing compounds that target the novel cancer-associated protein proliferation cell nuclear antigen (PCNA) to disrupt DNA replication and the ability for cancer cell growth.

Edwin Manuel, PhD
Dr. Manuel, Assistant Professor at the Department of Immuno-Oncology, received his PhD from Harvard University. Dr. Manuel is interested in understanding the escape mechanisms used by tumors to avoid immune recognition. He also developed a novel shRNA technology to down-regulate enzymes that contributes to immune suppression to improve immunotherapy.

Guido Marcucci, MD
Dr. Marcucci, Chair and Professor, Department of Hematologic Malignancies Translational Science, received his MD from Catholic University of the Sacred Heart. Dr. Marcucci is intensely interested in the pathogenesis, the maintenance and treatment of both chronic and acute myelogenous leukemia.

Jeannine McCune, PharmD
Dr. McCune, Professor at the Department of Population Sciences, received her PharmD from University of North Carolina. Her team is currently developing mathematical models to identify anticancer agent plasma exposure effective at treating cancer and modeling drug doses and frequencies to optimize treatment efficacy.
Kevin Morris, PhD
Dr. Morris, Professor of Center for Gene Therapy, received his PhD from UC Davis. His laboratory focuses on studying the role of noncoding RNAs in the evolution of cellular states as well as utilizing the inherent endogenous noncoding cellular mechanisms to control the expression of genes involved in human diseases.

Markus Müschen, MD, PhD
Dr. Müschen, Professor and Chair of the Department of Systems Biology, received his MD and PhD from the University of Cologne. His research focuses on understanding oncogenic signaling in acute lymphoblastic leukemia (AML). His team is developing a means to predict AML relapse and identifying therapeutic strategies to overcome such relapse.

Rama Natarajan, PhD
Dr. Natarajan, Professor and Chair of the Department of Diabetes Complications & Metabolism, received her PhD from Indian Institute of Science. The major focus of her research is to determine the molecular mechanisms involved in the accelerated development of inflammation, vascular and renal complications under diabetic conditions.

Susan Neuhausen, PhD
Dr. Neuhausen, Professor at the Department of Population Sciences, received her PhD from University of Minnesota. Her team focuses on identifying genetic, lifestyle, and environmental factors that cause breast, ovarian and prostate cancers, and to uncover what factors are important for disease-free survival in those who develop cancer.

Edward Newman, PhD
Dr. Newman, Associate Professor at the Department of Cancer Biology, received his PhD from Yale University. Dr. Newman is focused on studying the mechanism by which the inhibition of cytosine methylation in reactivating tumor suppressor gene expression and developing novel DNA methyltransferase inhibitors as effective cancer therapies.

Vu Ngo, PhD
Dr. Ngo, Associate Research Professor, Department of Systems Biology, received his Ph.D. from University of California, San Francisco. Dr. Ngo is focused on understanding the genetic and epigenetic mechanisms of cancer mutations resulting in cancers that are more aggressive and resistant to therapy.

Joyce Niland, PhD
Dr. Niland, Professor and Endowed Chair of the Department of Diabetes and Cancer Discovery Science, received her PhD from USC. She is Principal Investigator of the Human Islet Research Network Coordinating Center and the Integrated Islet Distribution Program to facilitate efficient use of these resources within the diabetes community for studying and treating type 1 diabetes.

Timothy O'Connor, PhD
Dr. O'Connor, Professor at the Department of Cancer Biology, received his PhD from Purdue University. His laboratory focuses on investigating DNA repair mechanisms in both normal and tumor cells and how those mechanisms can function either for use in therapeutic interventions or to evade treatment.

Javier Gordon Ogembo, PhD
Dr. Ogembo, Assistant Professor at the Department of Immuno-Oncology, received his Ph.D. from Nagoya University. Dr. Ogembo is studying how oncogenic viruses, such as Epstein-Barr virus and human papillomavirus, overcome cellular barriers and escape host immune responses, with the goal of using this knowledge to aid the development of effective vaccines.

Sunita Patel, PhD
Dr. Patel, Associate Clinical Professor in Population Sciences, received her Ph.D from Alliant University. She is identifying biological & environmental factors as either risk or protective factors for neurocognitive and psychosocial sequelae in cancer patients. Her work includes behavioral interventions to improve health disparities among ethnic minority survivors of childhood cancer.
Flavia Pichiorri, PhD
Dr. Pichiorri, Associate Professor at the Center for Multiple Myeloma Research, received her PhD from University of Rome. Her team works closely with the clinical team to investigate the molecular changes associated with the clinical response of multiple myeloma patients in the investigator initiated phase 1-2 clinical trials.

Christiane Querfeld, MD, PhD
Dr. Querfeld, Chief of Division of Dermatology and Assistant Clinical Professor at the Department of Pathology, received her MD and PhD from University of Cologne and University of Heidelberg, respectively. Dr. Querfeld's research focuses on understanding the biology of cutaneous lymphomas and developing therapies for this class of cancer.

Dan J. Raz, MD, MAS
Dr. Raz, Assistant Professor at the Department of Surgery, specializes in lung cancer surgery. His team focuses on targeting specific epigenetic marks to overcome therapy resistance in lung cancer. His team is active in drug discovery and use of human lung cancer tissue to test new therapeutics including 3D cell culture, tissue slice culture, and patient derived xenografts.

Anne Reb, PhD, NP
Dr. Reb, Assistant Professor of Division of Nursing Research and Education and the Department of Population Sciences, received her PhD from the Catholic University of America. Her research is directed at developing models of care to address areas of symptom management and cancer survivorship with particular emphasis on mind-body interventions.

Helena Reijonen, PhD
Dr. Reijonen, Associate Professor at the Department of Diabetes Immunology, received her PhD from University of Oulu and University of Turku. Dr. Reijonen's research is directed at understanding the autoimmunity response that leads to type 1 diabetes and limits the treatment of the disease following pancreatic islet cell transplantation.

Arthur Riggs, PhD
Dr. Riggs, Director of the Diabetes and Metabolism Research Institute at City of Hope, received his PhD from California Institute of Technology. Dr. Riggs's laboratory is focused on how gene regulation occurs via chromatin-based mechanisms and how this regulation changes during mammalian development.

Russell Rockne, PhD
Dr. Rockne, Assistant Professor at the Department of Computational and Quantitative Medicine, received his PhD from University of Washington. His work is based upon patient-specific mathematical models of cancer growth and response to therapy, with the goal of using mathematical models to quantify and predict disease dynamics and recurrence.

Andrei Rodin, PhD
Dr. Rodin, Associate Professor at the Department of Diabetes Complications and Metabolism, received his PhD from University of Texas Health Science Center, Houston. He is developing data analysis methodology and software to analyze large-scale data sets with an emphasis in understanding problems in molecular evolution.

Bart Roep, MD, PhD
Dr. Roep, Chair of the Department of Diabetes Immunology, received his PhD from Leiden University. His laboratory focuses on understanding the cause of immune response to insulin-producing beta cells and developing new strategy to modulate and desensitize immune response to beta cells for the cure of type 1 diabetes.

Steven Rosen, MD
Dr. Rosen, Provost & Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received his MD from Northwestern University. His team is developing novel therapies for hematologic malignancy by targeting ATP synthase, dihydroorotate dehydrogenase, histone deacetylase and de-ubiquinase.
**John Rossi, PhD**
Dr. Rossi, Chair of the Department of Molecular & Cellular Biology and Dean of Irell & Manella Graduate School of Biological Sciences, received his PhD from University of Connecticut. His laboratory focuses on developing RNA aptamers and cell internalizing delivery vehicle for the treatments of HIV infection and cancers.

**Ravi Salgia, MD, PhD**
Dr. Salgia, Professor and Chair of the Department of Medical Oncology and Therapeutics Research, Received his MD and PhD from Loyola University School of Medicine. Dr. Salgia is focused on identifying novel biomarkers for non-small cell lung cancer and developing targeted therapies related to lung cancer.

**Paul Salvaterra, PhD**
Dr. Salvaterra, Professor at the Department of Developmental and Stem Cell Biology, received his PhD from State University of New York, Buffalo. Dr. Salvaterra's research is directed at understanding the genetic determinants that affect neuronal cell fate and neurotransmitter phenotypes as a means of studying neurodegenerative diseases.

**Dustin Schones, PhD**
Dr. Schones, Associate Professor at the Department of Diabetes Complications and Metabolism, received his PhD from Stony Brook University NY. His team is using combined computational and experimental approaches to study the interaction of genetic and epigenetic variations in cancer, diabetes and obesity.

**Mina Sedrak, MD, MS**
Dr. Sedrak, Assistant Professor at the Department of Medical Oncology and Therapeutics Research, received his MD from Rush Medical College. Dr. Sedrak is focused on examining barriers to clinical trial participation for older adults with cancer as a way to improve evidence based cancer therapy for this population.

**Victoria Seewaldt, MD**
Dr. Seewaldt, Professor and Chair of the Department of Population Sciences, received her MD from UC Davis. Her research focuses on identifying signaling networks that promote breast cancer initiation with the goal of integrating novel functional imaging strategies with risk-marker to provide early detection of interval cancers.

**Binghui Shen, PhD**
Dr. Shen, Chair of the Department of Cancer Genetics and Epigenetics, received his PhD from Kansas State University. His team focuses on understanding the molecular functions of nucleases in DNA replication and repair, as well as identifying histone modifiers and their contribution to cancer.

**Yanhong Shi, PhD**
Dr. Shi, Professor at the Department of Developmental & Stem Cell Biology, received her PhD from Northwestern University. Her laboratory focuses on characterizing the role of the nuclear receptor TLX signaling in neural stem cell self-renewal and differentiation for developing new treatment against neurological disorders.

**Hung-Ping (Ben) Shih, PhD**
Dr. Shih, Assistant Professor at the Department of Translational Research & Cellular Therapeutic, received his PhD from Oregon State University. His laboratory focuses on defining the molecular control of organ morphogenesis and the interplay between morphogenesis and cell-fate decisions during pancreatic development.

**John Shively, PhD**
Dr. Shively, Professor at the Department of Molecular Imaging and Therapy, received his PhD from University of Illinois-Urbana-Champaign. One of the major focuses of Dr. Shively's laboratory is to explore the potential of using anti-carcinoembryonic antigen antibodies to image tumor targets in vivo.
Christopher Sistrunk, PhD
Dr. Sistrunk, Assistant Professor at the Department of Population Sciences, received his PhD from North Carolina State University. His team utilizes molecular pathology techniques to elicit specific biochemical profiles that can identify tumorigenesis at early time point than our current standard of care diagnosis tools.

Steven Smith, PhD
Dr. Smith, Professor Emeritus at the Department of Hematologic Malignancies Translational Science, received his PhD from UCLA. He studies the influence of dynamic DNA structures on genetic and epigenetic DNA damage during carcinogenesis and aging. Current experiments investigate DNA quadruplex linked double-strand breaks, slippage and DNA methylation.

Jeremy Stark, PhD
Dr. Stark, Professor at the Department of Cancer Genetics and Epigenetics, received his PhD from University of Washington. His team seeks to define the factors that limit chromosomal rearrangements during DNA double-stranded break repair to maintain genome stability, and to develop therapeutic targets for tumor radiosensitization.

Cy Aaron Stein, MD, PhD
Dr. Stein, Professor at the Department of Medical Oncology and Therapeutics Research, received his MD from Albert Einstein College of Medicine and his PhD from Stanford University. Dr. Stein's research team focuses on identifying effective strategies to improve the delivery of gene silencing oligonucleotides into cells for cancer therapy.

Zijie (ZJ) Sun, MD, PhD
Dr. Sun is a Professor at the Department of Cancer Biology. His research interest is focused on transcriptional control and cell signaling in development and tumorigenesis, especially using a variety of "cutting-edge" experimental approaches to uncover genomic and epigenetic alternations during the course of these biologic events.

Zuoming Sun, PhD
Dr. Sun, Professor at the Department of Molecular Imaging & Therapy, received his PhD from Duke University. His research team focuses on understanding the mechanisms responsible for the regulation of T cell activation so as to develop effective and safe treatments for immune disorders.

Timothy Synold, PharmD
Dr. Synold, Professor of Cancer Biology and the Director of Analytic Pharmacology Core, received his PharmD from UCSF. In his numerous collaborations with City of Hope investigators, his team is responsible for the design and conduct of preclinical phase 1 and 2 pharmacokinetic investigations of anti-cancer agents.

John Termini, PhD
Dr. Termini, Professor at the Department of Molecular Medicine and Director of Shared Resources, received his PhD from Columbia University. His team utilizes synthetic DNA chemistry and analytical methodologies to define how specific DNA base damage accumulates under physiological conditions to promote mutagenesis and cancer.

Debbie Thurmond, PhD
Dr. Thurmond, Professor and Chair of the Department of Molecular and Cellular Endocrinology, received her PhD from University of Iowa. Dr. Thurmond’s research focuses on understanding the cellular and molecular mechanisms involved with diabetes development and identifying therapies to reverse the progression of the disease.

Lindsey Treviño, PhD
Dr. Treviño, Assistant Professor at the Department of Population Sciences, received her PhD from Cornell University. Dr. Treviño 's research is directed at understanding the molecular basis by which exposure to endocrine disrupting chemicals affects the epigenetic machinery leading to a variety of metabolic disorders including cancer, obesity and diabetes.
Nagarajan Vaidehi, PhD
Dr. Vaidehi, Professor at the Department of Molecular Imaging & Therapy, received her PhD from Indian Institute of Technology. Her laboratory focuses on developing and applying computational methods to study the structure and dynamics of membrane proteins and protein-protein interactions for identifying small molecule inhibitors.

Rupangi Vasavada, PhD
Dr. Vasavada, Associate Professor at the Department of Translational Research and Cellular Therapeutics, received her PhD from University of Pennsylvania. Her work focuses on understanding how biological peptides may enhance the preservation and regeneration of functional beta cells as a treatment for diabetes.

Edward Wenge Wang, MD, PhD
Dr. Wang, Assistant Professor and Medical Oncologist at the Department of Medical Oncology and Therapeutics Research, received his MD, PhD from Harbin Medical University. He leads a laboratory at the Biomedical Research Center, focusing on development of new death receptor agonists and rescue of p53 from negative regulators for cancer treatment.

Leo Wang, MD, PhD
Dr. Wang, Assistant Professor at the Department of Immuno-Oncology, received his MD and PhD from the University of Chicago. Dr. Wang's lab uses molecular and cellular techniques to identify non-genetic determinants leading to functional differences in blood cells at different stages of development.

Lili Wang, MD, PhD
Dr. Wang, Associate Professor at the Department of Systems Biology, received her MD from China Medical University and her PhD from Tokai University. Dr. Wang's research involves understanding how somatic mutations contribute to the development of chronic lymphocytic leukemia.

Qiong (Annabel) Wang PhD
Dr. Wang, Assistant Professor at the Department of Molecular and Cellular Endocrinology. Her team focuses on defining the mechanisms of adipose tissue remodeling in mammary glands to prevent metabolic disorders and breast cancer, as well as brown adipocyte heterogeneity in remodeling the energy-burning capacity in brown adipocytes.

Sophia Wang, PhD
Dr. Wang, Professor at the Department of Computation and Quantitative Medicine, received her PhD from Johns Hopkins Bloomberg School of Public Health. Her research is focused on the etiology of hematopoietic malignancies and the role that immune genes, which play a role in inflammation, impact lymphoma etiology and survival.

Jeffrey Weitzel, MD
Dr. Weitzel, Professor at the Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, received his MD from University of Minnesota Medical School. Dr. Weitzel's research is focused on genetic cancer risk assessment, particular in minority populations, which may be under served.

John Williams, PhD
Dr. Williams, Professor at the Department of Molecular Medicine, received his PhD from Columbia University. His group utilizes X-ray crystallography and biophysical methods to design, quantify and optimize novel therapeutics, including monoclonal antibodies and STAT3 inhibitor, for cancer treatment.

F. Lennie Wong PhD
Dr. Wong, Associate Professor at the Departments of Population Sciences and Computational and Quantitative Medicine, Division of Biostatistics, received her PhD from UCLA. She uses computer modeling to address the long-term health issues that childhood cancer survivors may face.
Anna Wu, PhD
Dr. Wu, Professor and Chair of the Department of Molecular Imaging and Therapy, received her PhD from Yale University. Dr. Wu's research team focuses on engineering antibodies specific to tumor antigens for developing novel imaging technology to aid in the in vivo detection of tumors.

Yanzhong Yang, MD, PhD
Dr. Yang, Assistant Professor at the Department of Cancer Genetics & Epigenetics, received his PhD from Fudan University. Research in his laboratory aims to identify altered epigenetic pathways that lead to tumorigenesis and to develop novel strategies to target these pathways for cancer therapy.

Jiing-Kuan Yee, PhD
Dr. Yee, Professor at the Department of Diabetes Complications & Metabolism, received his PhD from University of Texas - Dallas. His laboratory focuses on developing novel human pluripotent stem cell differentiation protocol to produce functional beta islet cells in clinical relevant quality and quantity for the treatment of diabetes.

Hua Yu, PhD
Dr. Yu, Professor of the Department of Immuno-Oncology, received her PhD from Columbia University. Dr. Yu's research team examines the role of STAT3 in mediating the tumor microenvironment. The eventual goal is to devise therapies to target STAT3 leading to tumor death.

Jianhua Yu, PhD
Dr. Yu, Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received his PhD from Purdue University. His research team focuses on engineering CAR Natural Killer cells, CAR T cells, oncolytic virus and bispecific antibodies, natural product-based strategies and hematopoietic cell transplantation for cancer therapy.

Xiaochun Yu, MD, PhD
Dr. Yu, Professor at the Department of Cancer Genetics & Epigenetics, received his PhD from Kurume University. His team uses multidisciplinary approaches to identify novel signal transduction pathways mediated by post-translational modifications in DNA damage response and repair to preserve genome integrity.

Yuan Yuan, MD, PhD
Dr. Yuan, Associate Professor at the Department of Medical Oncology and Therapeutics Research, receive her MD and PhD from Xuzhou Medical College and UC Riverside, respectively. She is interested in developing novel therapeutics for metastatic triple negative breast cancer. She is currently involved in a number of clinical trials testing these therapies.

John Zaia, MD
Dr. Zaia, Director of Center for Gene Therapy, received his MD from Harvard Medical School. His team collaborates with City of Hope investigators to test various approaches, including genome editing of the CCR5 gene important for HIV infection, in providing resistance to HIV infection and slowing the progression of AIDS.

Defu Zeng, MD
Dr. Zeng, Professor of Diabetes Immunology, received his PhD from Fujian Medical University. His laboratory focuses on understanding the pathogenesis of graft-versus-host disease, which is a major obstacle in allogenic hematopoietic cell transplantation for the treatment of hematological malignancies.